IGC Pharma (IGC) Share-based Compensation (2011 - 2025)

IGC Pharma (IGC) has reported Share-based Compensation for 15 consecutive years, with $3.8 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Share-based Compensation rose 843.53% year-over-year to $3.8 million in Q3 2025; TTM through Sep 2025 was $12.4 million, a 645.15% increase from a year earlier, with the FY2026 full-year figure at $4.0 million, down 6.98% from the prior year.
• Share-based Compensation was $3.8 million for Q3 2025 at IGC Pharma, down from $4.7 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $4.7 million in Q2 2025 and troughed at $125000.0 in Q2 2021.
• A 5-year average of $1.1 million and a median of $523000.0 in 2021 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation slumped 69.01% in 2023 and soared 1069.15% in 2025, its largest moves.
• Over 5 years, Share-based Compensation stood at $523000.0 in 2021, then fell by 7.46% to $484000.0 in 2022, then advanced by 8.68% to $526000.0 in 2023, then surged by 564.64% to $3.5 million in 2024, then rose by 8.5% to $3.8 million in 2025.
• The last three Share-based Compensation figures came in at $3.8 million (Q3 2025), $4.7 million (Q2 2025), and $455000.0 (Q1 2025), per Business Quant data.